Principles of Clinical PharmacologyArthur J. Atkinson Jr., Darrell R. Abernethy, Charles E. Daniels, Robert Dedrick, Sanford P. Markey Elsevier, 2011. gada 28. apr. - 568 lappuses This revised second edition covers the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development, focusing on the fundamentals that underlie the clinical use and contemporary development of pharmaceuticals. Authors drawn from academia, the pharmaceutical industry and government agencies cover the spectrum of material, including pharmacokinetic practice questions, covered by the basic science section of the certifying examination offered by the American Board of Clinical Pharmacology. This unique reference is recommended by the Board as a study text and includes modules on drug discovery and development to assist students as well as practicing pharmacologists.
|
No grāmatas satura
1.–5. rezultāts no 72.
xi. lappuse
... Drug Therapy CHARLES E. DANIELS Introduction 403 Adverse Drug Events 403 Medication Use Process 404 Improving the Quality of Medication Use 405 Organizational Influences On ... Drug Development CHRIS H. TAKIMOTO AND MICHAEL Contents xi.
... Drug Therapy CHARLES E. DANIELS Introduction 403 Adverse Drug Events 403 Medication Use Process 404 Improving the Quality of Medication Use 405 Organizational Influences On ... Drug Development CHRIS H. TAKIMOTO AND MICHAEL Contents xi.
xii. lappuse
... Drug Development CHRIS H. TAKIMOTO AND MICHAEL WICK INTRODUCTION 449 Components of Preclinical Drug Development 450 In Vitro Studies 450 Drug Supply and Formulation 451 In Vivo Studies — Efficacy Testing in Animal Models 452 In Vivo ...
... Drug Development CHRIS H. TAKIMOTO AND MICHAEL WICK INTRODUCTION 449 Components of Preclinical Drug Development 450 In Vitro Studies 450 Drug Supply and Formulation 451 In Vivo Studies — Efficacy Testing in Animal Models 452 In Vivo ...
xiii. lappuse
... Drug Development Paradigms 507 Label-Driven Question-Based Clinical Development Plan Paradigm 507 Differentiation Paradigm 507 Drug Action → Response → Outcome → Benefit Paradigm 508 Learning vs Confirming Paradigm 508 Decision ...
... Drug Development Paradigms 507 Label-Driven Question-Based Clinical Development Plan Paradigm 507 Differentiation Paradigm 507 Drug Action → Response → Outcome → Benefit Paradigm 508 Learning vs Confirming Paradigm 508 Decision ...
xviii. lappuse
... Drug Metabolism and Pharmacokinetics Los Altos, CA 94024 Charles V. Grudzinskas Center for Drug Development Science University of California, San Francisco; UC Washington Center Washington, DC 20036 Nicholas H.G. Holford University of ...
... Drug Metabolism and Pharmacokinetics Los Altos, CA 94024 Charles V. Grudzinskas Center for Drug Development Science University of California, San Francisco; UC Washington Center Washington, DC 20036 Nicholas H.G. Holford University of ...
2. lappuse
... Drug, and Cosmetic Act. This act greatly expanded the scope of the FDA's mandate to protect the public health. The thalidomide tragedy also provided the major impetus for developing a number of NIH-funded academic centers of excellence ...
... Drug, and Cosmetic Act. This act greatly expanded the scope of the FDA's mandate to protect the public health. The thalidomide tragedy also provided the major impetus for developing a number of NIH-funded academic centers of excellence ...
Saturs
1 | |
9 | |
DRUG METABOLISM AND TRANSPORT | 141 |
ASSESSMENT OF DRUG EFFECTS | 273 |
OPTIMIZING AND EVALUATING PATIENT THERAPHY | 323 |
DRUG DISCOVERY AND DEVELOPMENT | 421 |
APPENDIX I Abbreviated Tables of Laplace Transforms | 527 |
APPENDIX II Answers to Study Problems | 529 |
Index | 537 |
Citi izdevumi - Skatīt visu
Principles of Clinical Pharmacology Arthur J. Atkinson Jr.,Arthur J. Atkinson Ierobežota priekšskatīšana - 2001 |
Principles of Clinical Pharmacology Arthur J. Atkinson Jr.,Charles E. Daniels,Robert Dedrick,Charles V. Grudzinskas,Sanford P. Markey Priekšskatījums nav pieejams - 2001 |
Bieži izmantoti vārdi un frāzes
absorption acid activity addition administration adverse agents analysis approach binding blood body cancer cause cells changes Chapter clearance Clin Pharmacol Ther clinical compartment compounds concentration decrease described determined differences digoxin disease distribution dose drug development effect elimination enzyme Equation errors estimate et al evaluation example expression factor Figure flow function gene half-life hepatic human identified important increased individuals infusion inhibition inhibitors initial interactions kinetics levels liver measured mechanism medication metabolism metabolites methods molecular needed normal observed occur oral organic P-glycoprotein parameters patients pharmacokinetics pharmacology Phase plasma population potential predicted pregnancy protein reactions receptor reduced relationship relative renal reported response result risk selection shown specific studies substrate Table therapeutic therapy tion tissue toxicity transport treated treatment trials tumor volume women
Populāri fragmenti
339. lappuse - There are. however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed Nursing Mothers: It is not known whether this drug is excreted in human milk.
403. lappuse - Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer.
285. lappuse - Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
285. lappuse - The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute.
223. lappuse - P (1994). Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the bloodbrain barrier and to increased sensitivity to drugs. Cell, 77: 491-502.
268. lappuse - Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther.
7. lappuse - Pratt WB, Taylor P, eds. Principles of drug action: The basis of pharmacology. 3rd ed.
285. lappuse - Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context.
Atsauces uz šo grāmatu
Bioequivalence and Statistics in Clinical Pharmacology Scott D. Patterson,Byron Jones Ierobežota priekšskatīšana - 2005 |
Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition Daan J. A. Crommelin,Robert D. Sindelar,Bernd Meibohm Priekšskatījums nav pieejams - 2007 |